NCT01466738View on ClinicalTrials.gov

A Study of Human Rhinovirus Type 16 (HRV-16) Following Administration in the Nose of Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Healthy
Interventions
BIOLOGICAL

HRV-16 (100 TCID50)

Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.

BIOLOGICAL

HRV-16 (1000 TCID50)

Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.

Trial Locations (1)

Unknown

Charlottesville

All Listed Sponsors
lead

Centocor Ortho Biotech Services, L.L.C.

INDUSTRY

NCT01466738 - A Study of Human Rhinovirus Type 16 (HRV-16) Following Administration in the Nose of Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter